<- Go Home
Vimian Group AB (publ)
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, education, and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and surgical and dental products to veterinary clinics and universities, including dentistry and companion animal orthopedics under the Movora brand name. Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.
Market Cap
SEK 1.5B
Volume
439.3K
Cash and Equivalents
SEK 50.4M
EBITDA
SEK 104.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
SEK 299.2M
Profit Margin
69.00%
52 Week High
SEK 3.95
52 Week Low
SEK 2.19
Dividend
N/A
Price / Book Value
2.01
Price / Earnings
39.33
Price / Tangible Book Value
-10.37
Enterprise Value
SEK 1.7B
Enterprise Value / EBITDA
15.51
Operating Income
SEK 73.3M
Return on Equity
5.29%
Return on Assets
4.06
Cash and Short Term Investments
SEK 50.4M
Debt
SEK 247.8M
Equity
SEK 730.0M
Revenue
SEK 433.6M
Unlevered FCF
SEK 66.6M
Sector
Health Care Equipment and Supplies
Category
N/A